Seeing Is Believing
Currently out of the existing stock ratings of Robyn Karnauskas, 304 are a BUY (84.68%), 54 are a HOLD (15.04%), 1 are a SELL (0.28%).
Analyst Robyn Karnauskas, carries an average stock price target met ratio of 50.9% that have a potential upside of 41.87% achieved within 346 days. Previously, Robyn Karnauskas worked at TRUIST.
Robyn Karnauskas’s has documented 734 price targets and ratings displayed on 45 stocks. The coverage was on the Healthcare sector.
Most recent stock forecast was given on TRML, Tourmaline Bio at 09-Sep-2025.
Analyst best performing recommendations are on DRNA (DICERNA PHARMACEUTICALS).
The best stock recommendation documented was for DRNA (DICERNA PHARMACEUTICALS) at 11/18/2019. The price target of $24 was fulfilled within 1 day with a profit of $2.61 (12.2%) receiving and performance score of 122.02.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy
$284
$53.5 (23.21%)
$220
6 days ago
(10-Oct-2025)
43/44 (97.73%)
$53.5 (23.21%)
593
Hold
$251
$20.5 (8.89%)
$205
13 days ago
(03-Oct-2025)
15/16 (93.75%)
$17.09 (7.31%)
300
Buy
$270
$39.5 (17.14%)
$195
29 days ago
(17-Sep-2025)
2/3 (66.67%)
$49.19 (22.28%)
121
Buy
$235
$4.5 (1.95%)
$200
1 months ago
(16-Sep-2025)
14/14 (100%)
$18.74 (8.67%)
483
Buy
$245
$14.5 (6.29%)
$210
1 months 1 days ago
(15-Sep-2025)
16/17 (94.12%)
$27.39 (12.59%)
244
Which stock is Robyn Karnauskas is most bullish on?
Which stock is Robyn Karnauskas is most reserved on?
What Year was the first public recommendation made by Robyn Karnauskas?